AGITATION IN DELIRIUM MANAGEMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Agitation in Delirium Management Market– Drivers

• Increasing incidence of delirium: The increasing incidence of delirium among patients admitted to intensive care unit (ICU) is expected to drive the global agitation in delirium management market growth over the forecast period. For instance, in September 2022, according to the data published by Hindwai, a a publisher of peer-reviewed, open access, scientific journals currently active in scientific, technical, and medical literature, the incidence of delirium was up to 46.3% among patients admitted to the ICU.

Global Agitation in Delirium Management Market: Restraint

• High cost of treatment: The high cost of treatment is significantly restraining the growth of the global agitation in delirium management market. For instance, according to a study published by the U.S. National Library of Medicine in 2020, the average daily cost of pharmacotherapy for delirium in the U.S. was US$105. This included the costs of drugs like haloperidol, olanzapine, ziprasidone, and risperidone, which are commonly used to treat agitation in delirium patients. The study analyzed data on pharmacotherapy costs from 1450 patients aged 65 years and older admitted to multiple hospitals in the country. It was reported that antipsychotic medications accounted for over 60% of the total pharmacotherapy costs for delirium management. Given the effective nature of these drugs, their usage is often limited in many healthcare systems worldwide due to budget constraints. Key players are focusing on developing advancing products with safety and cost effective, and this is expected to drive market growth over the forecast period.